MediMedia Managed Markets
Managed Care magazine
P&T Community, The Online Resource for P&T Decision Makers
Login / Register
Join Us  Facebook  Twitter  Linked In
About P&T Journal
Editorial: Sonja Sherritze, Editor
Advertising: Maureen Dwyer Liberti,
    Vice President, Group Publisher

Production: Mary Ellen Curry,
    Director of Production Services

Circulation: Jackie Ott, Circulation Manager

Statement of Purpose
Guidelines for Authors
Editorial Board

Recent Issues

November 2004


Meeting Highlights

Neuroscience 2004: 34th Annual Meeting of the Society for Neuroscience

Dr. Prescott reviews advances in therapies for Alzheimer’s disease, Parkinson’s disease, autism, schizophrenia, methamphetamine addiction, and cognition in Down syndrome as well as a possible relationship between isotretinoin and depression.
Lawrence M. Prescott, PhD

Demographics, Practices, and Prescribing Characteristics of Physicians Who Are Early Adopters of New Drugs

The factors that influence physicians to prescribe novel first-in-class drugs and later follow-on (established) drugs are explored.
Harold E. Glass, PhD, and Bruce Rosenthal, MBA

Contemporary Issues Affecting P&T Committees.
Part 1: The Evolution

The authors discuss the origins of drug formularies and the changing role of P&T committees.
Sanjeev Balu, BPharm, MBA, Paul O’Connor, RPh, MBA, and F. Randy Vogenberg, RPh, PhD

Off-Label Use of Recombinant Activated Factor VII (NovoSeven®)

The authors review a coagulation factor therapy for patients at risk for bleeding.
Thomas A. Ratko, PhD, Joseph P. Cummings, PhD, and Karl A. Matuszewski, MS, PharmD

Treatment of Acute Otitis Media in Children with Tympanostomy Tubes: A Caregiver’s Perspective

Caregivers of pediatric patients with AOMT were more satisfied with ciprofloxacin/dexamethasone than ofloxacin in healing otorrhea.
Curtis Waycaster, PhD, Paul Cockrum, PharmD, Bradley Reese, MD, Brent Lanier, MD, and G. Michael Wall, PhD

Drug Safety Revisions: FDA Update

The FDA has issued new labeling changes for efavirenz, rituximab, levothyroxine, zoledronic acid, infliximab, and some of the second-generation antidepressants.
Marvin M. Goldenberg, PhD, RPh, MS



Strategic Tools, Strategic Decisions

David Nash, MD, MBA, presents some examples of cutting-edge, “disruptive” technology, which has the potential to turn current practice on its head.
David Nash, MD, MBA

Medication Errors

Supervision Is Often a Weak Link in Error Prevention

Matthew Grissinger, RPh, FASCP, discusses job satisfaction, productivity, and the qualities of successful supervisors, as perceived by employees, that can lead to a reduction of errors.
Matthew Grissinger, RPh, FASCP

Prescription: Washington

Role of P&T Committees in Medicare: How Much Authority, Accountability?

Stephen Barlas discusses the debate surrounding the changing face of P&T committees and their increased authority with the advent of the new Medicare drug benefit plans.
Stephen Barlas

New Drugs/Drug News/New Medical Devices

P&T presents the latest information about FDA approvals, drug indications, industry updates, and new devices.